<DOC>
	<DOC>NCT02026362</DOC>
	<brief_summary>To prove that the efficacy and safety of 'MASCT group' is superior to 'non-treatment group' in patient undergone curative resection (RFA or operation) for hepatocellular carcinoma in China.</brief_summary>
	<brief_title>Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. The patient is diagnosed as hepatocellular carcinoma(HCC); 2. The patient underwent radical operation of HCC within 8 weeks before enrollment; 3. The number of tumors≤2； 4. No cancer embolus in the main portal vein and first branch, hepatic duct and first branch, hepatic vein, inferior vena cava; 5. No portal lymph node metastasis； 6. No extrahepatic metastasis; 7. Complete tumor resection without residual tumor at the surgical margins should be confirmed by enhanced CT or MRI imaging within 4 week (including 4 weeks) after radical operation; 8. If an increased serum AFP level was detected of the patient before the radical operation, the AFP level should be returned to normal in 8 weeks; 9. ChildPugh Score ≤9; 10. ECOG Performance status (ECOGPS) ≤2 ; 11. The expected survival time &gt; 2 years; 12. Tests of blood,liver and kidney should meet the following criteria： WBC&gt;3×109/L Neutrophil counts &gt;1.5×109/L Hemoglobin ≥85 g/L Platelet counts≥50×109/L PT is normal or The extend time ＜3s BUN≤1.5 times the upperlimit , Serum creatinine≤ 1.5 times of the upperlimit 13. Sign the informed consent. 1. Women who is pregnant or during breast feeding or plan to pregnant in 2 years; 2. Extrahepatic metastasis or liver residual tumor; 3. Cancer embolus in the main portal vein and first branch, Hepatic duct and first branch, hepatic vein, inferior vena cava; 4. 6 months before enrollment: the period of systemic and continuous use of immunomodulatory agents (such as interferon, thymosin, traditional Chinese medicine) was longer than 3 months; 5. 6 months before enrollment: the period of systemic and continuous use of the immunosuppressive drugs (such as corticosteroids drug) was longer than 1 months; 6. Received any cell therapy (including NK, CIK, DC, CTL, stem cells therapy) in 6 months before enrollment; 7. Positive for HIV antibody or HCV antibody; 8. Have a history of immunodeficiency disease or autoimmune diseases (such as rheumatoid arthritis, Buerger's disease, multiple sclerosis and diabetes type 1); 9. Patient who suffered from other malignant tumor in 5 years before enrollment (except skin cancer, localized prostate cancer or cervix carcinoma); 10. . Patients with organ failure; 11. Patients with serious mental disease; 12. Drug addiction in 1year before enrollment (including alcoholics); 13. Participated in other clinical trials in 3 months before screening; 14. Other reasons the researchers think not suitable.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HCC</keyword>
	<keyword>DC</keyword>
	<keyword>CTL</keyword>
</DOC>